SEC Comment Letter for Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — May 14, 2020
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: May 14, 2020 · CIK: 0001262104 · Accession: 0000000000-20-004278
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238056
Letter
United States securities and exchange commission logo May 13, 2020 Daniel P. Gold, Ph.D. President & Chief Executive Officer MEI Pharma, Inc. 3611 Valley Centre Drive, Suite 500 San Diego, California 92130 Re:MEI Pharma, Inc. Registration Statement on Form S-3 Filed May 7, 2020 File No. 333-238056 Dear Dr. Gold: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Finnbarr D. Murphy
Show Raw Text
United States securities and exchange commission logo
May 13, 2020
Daniel P. Gold, Ph.D.
President & Chief Executive Officer
MEI Pharma, Inc.
3611 Valley Centre Drive, Suite 500
San Diego, California 92130
Re:MEI Pharma, Inc.
Registration Statement on Form S-3
Filed May 7, 2020
File No. 333-238056
Dear Dr. Gold:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Finnbarr D. Murphy